TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Conversion from BCT ineligibility to BCT eligibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of photodynamic therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Hazard Ratio of Anastrozole vs. Tamoxifen
Endpoint domain: Mortality/survival
Primary endpoint: HAQ‐DI scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Association between smoking and Parkinson disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Association between automobile speed propensity and Parkinson disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Association between number of sexual partners and Parkinson disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: endurance time during CWRCE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satellite cell activity expressed by Ki67/CD56
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PI3K/Akt protein expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mTOR protein expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: A(1C) level change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: SMBG compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction with SMBG
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Serum levels of NT-proBNP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Processing of positively valenced material
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ED50 end‐tidal sevoflurane concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ED95 end‐tidal sevoflurane concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to end‐tidal sevoflurane concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recovery of arm function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recognition of adverse effects of medications
Endpoint domain: Adverse events/effects
Primary endpoint: plaque formation on dental implants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retear rate
Endpoint domain: Adverse events/effects
Primary endpoint: Acute rejections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: ACh-induced vasodilation responsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Risk of outdoor falls
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of nonserious injurious falls
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improving nighttime and daytime asthma symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reducing use of breakthrough medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: improving morning peak expiratory flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: ZAN-BPD score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in frequency of ischaemic episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in duration of ischaemic episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pain score 24 h postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemidiaphragmatic paresis
Endpoint domain: Adverse events/effects
Primary endpoint: Intradermal Test Concentration (ITC) of allergens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30-day rate of death or nonfatal myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: rates of death, nonfatal myocardial infarction, or nonfatal major bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Time required to measure RI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reincarceration rate
Endpoint domain: Mortality/survival
Primary endpoint: Mean pain scores on the day of discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean use of additional analgesia (intravenous morphine equivalents)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 30-day death, myocardial infarction, or urgent target vessel revascularization
Endpoint domain: Mortality/survival
Primary endpoint: Risk of severe or moderate bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: 40-month actuarial survival
Endpoint domain: Mortality/survival
Primary endpoint: Symptomatic improvement in NYHA functional class
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Focused attention improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Z-scores for wasting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Z-scores for underweight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Acceptability of the interactive Internet platform
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Feasibility of the interactive Internet platform
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time to oral diet
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Relief of dyspnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to orientation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: transition to psychosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of outliers regarding HKA > ±3°
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-intervention physical activity changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: One-year physical activity changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urgent target vessel revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: structural progression of medial knee osteoarthritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Total cholesterol to HDL cholesterol ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CD4+ T-cell count change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CD4+/CD8+ ratio change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: clinical outcome at 1-year follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mouth-opening (inter-incisal distances)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fraction of time esophageal pH was <4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reflux frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reflux duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: 24-hour trough intraocular pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Logged into portals ≥1 time within 7 days of discharge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean number of logins
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Satisfaction with the bedside tablet to access the portal
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Nerve function (VT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: mean ADHD-RS total score change at end-point
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opt for resuscitation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cases of violence detected
Endpoint domain: Adverse events/effects
Primary endpoint: Rates of psychiatric disorder
Endpoint domain: Adverse events/effects
Primary endpoint: Mean maximal concentrations (Cmax) of THC and 11-OH-THC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 'High' feeling
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Likelihood of follow-up with PCP
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: post‐traumatic stress disorder symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in trough FEV1 from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Median trial start-up time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Inclusion rate per site per month
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage completed follow-ups
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percent recovery of WMSI on day 10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage feedback inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Anterior chamber fluorescein concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circulating CD3 cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Circulating CD4 cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Disruptive-total of the parent-rated Nisonger Child Behavior Rating Form
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Isometric muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Explosive muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Muscle mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Height deficit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discrimination of ophthalmic disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of active labour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Echolucency measurements of the far wall common carotid intima-media
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Distance covered in 6-minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean percentage of repigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mean exam scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: unfavorable outcome
Endpoint domain: Mortality/survival
Primary endpoint: Ability to respond mindfully to stressful internal events
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevalence rate of PDC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence rates for aplasia of the second premolars
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence rates for aplasia of the maxillary lateral incisors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: successful visualization of biliary and pancreatic ducts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: luminal narrowing throughout the pancreatic duct
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: morphological findings consistent with surgical findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual field deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative hernia development
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of severe neutropenia in cycle 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: First-time success rate for PLMA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean oropharyngeal leak pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to clinical stabilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CanSORT score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: BREAST-Q Physical Well-Being
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Adverse Radiation Effects
Endpoint domain: Adverse events/effects
Primary endpoint: headache pain freedom
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: most bothersome symptom freedom
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of energy expenditure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Enjoyment of AVG's compared to exercise trials
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Core flow
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Acceptability of MTOP
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Experience of care scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Crohn's Disease Activity Index (CDAI) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Crohn's disease-related hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Improvement in total Y‐BOCS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of pathogenicity of subgingival microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of microbial diversity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of periodontitis‐associated microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perceptions of quality of care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: blood flow in the popliteal artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: blood flow in the posterior tibial artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Delayed HBV vaccination response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antibody titer level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: alfentanil consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local tolerability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Adhesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: fibrinopeptide A levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum concentrations of N-terminal pro-B-type natriuretic peptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: security of the supplied contraceptive methods
Endpoint domain: Adverse events/effects
Primary endpoint: development of side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Intestinal microbial diversity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of isovaleric acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concentration of valeric acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Success rate of suprapubic aspiration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean activity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asthma symptoms control
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Traumatic grief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-traumatic avoidance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: weekly vomiting frequency (WVF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postprandial fat oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of pancreatic infectious complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Frequency of multiple organ failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of abdominal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of glare
Endpoint domain: Adverse events/effects
Primary endpoint: symptoms of dysphotopsia
Endpoint domain: Adverse events/effects
Primary endpoint: satisfaction with eyesight
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Nonfatal disabling stroke rate
Endpoint domain: Adverse events/effects
Primary endpoint: Paravalvular regurgitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean cumulative number of GEL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduced mean GEL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decreased wound days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Nd:YAG capsulotomy
Endpoint domain: Adverse events/effects
Primary endpoint: Contrast visual acuity with and without glare
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge improvement percentage
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 30-day readmission rates for MI
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 30-day readmission rates for HF
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 30-day readmission rates for pneumonia
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time to first bowel emptying
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Perceived discomfort on Day 4
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: bioavailability of EE2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sheehan Disability Scale mean score
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Driving cessation
Endpoint domain: Mortality/survival
Primary endpoint: Recurrence of actinic keratosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cosmetic outcome characterized by hypopigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain tolerance
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in pain during sexual activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in grocery costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: recurrence rate after pterygium surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: abnormal endometrial morphology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ER immunoreactivity levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Systemic reactions to insect stings
Endpoint domain: Adverse events/effects
Primary endpoint: Energetic cost of walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma selenium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: GPx3 activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxidized LDL levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: serious bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of another disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thymic function (TI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: TREC levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Naïve T-cell counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes